Precirix, a VUB spin-off, has successfully produced the first clinical trial batch of CAM-H2, a precision radiopharmaceutical for cancer treatment. The production took place at Evergreen Theragnostics' advanced facility in New Jersey, USA. Precirix is currently conducting a Phase I/II clinical trial in Canada to assess the safety and effectiveness of CAM-H2 in HER2-positive metastatic breast, gastric, and gastroesophageal cancer patients, including those with brain metastases.
Evergreen will manufacture CAM-H2 in both therapeutic and imaging doses, allowing patients to receive imaging doses to evaluate HER2 expression before potentially qualifying for therapeutic treatment with CAM-H2. Both companies express enthusiasm for their collaboration and the opportunity to evaluate CAM-H2 in patients across North America.